On June 15, 2020, Tocagen Inc. completed its business combination with Forte Biosciences Inc., which changed its name in connection with the transaction to “Forte Subsidiary Inc.” (“Forte”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated February 19, 2020, as amended by that certain amendment dated May 11, 2020, by and among the Company, Telluride Merger Sub Inc., and Forte, pursuant to which Merger Sub merged with and into Forte, with Forte surviving as a wholly owned subsidiary of the Company. Pursuant to the Merger Agreement, on June 15, 2020, effective as of the Effective Time, the company terminated the employment of Martin J. Duvall, the Company’s Chief Executive Officer and appointed Paul A. Wagner, Ph.D., as the company’s Chief Executive Officer. Dr. Wagner founded Forte, has served as President and Chief Executive Officer of Forte since 2018, and has served as a member of Forte’s board of directors since 2017.